Rebimastat

DRACPC ID  DRACPC0043

Active Ingredients   Rebimastat

Description  A sulfhydryl-based second-generation matrix metalloproteinase (MMP) inhibitor with potential antineoplastic activity. Rebimastat selectively inhibits several MMPs (MMP 1, 2, 8, 9, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

Synonyms  BMS-275291; D2163; N-((2S)-2-Mercapto-1-oxo-4-(3,4,4-trimethyl-2,5-dioxo-1-imidazolidinyl)butyl)-L-leucyl-N,3-dimethyl-L-valinamide; Rebimastat

Type  Small Molecule

Disease  Lung cancer, Prostate cancer

Classification

  

MMP inhibitor Peptide and derivative

Structure Information


Molecular Formula  C23H41N5O5S

Molecular Weight  499.7

Active Sequence  Not available

Sequence Length  Not available

Modification  Not available

Structure

 

Show IUPAC/InChI/SMILES

IUPAC Name  (2S)-N-[(2S)-3,3-dimethyl-1-(methylamino)-1-oxobutan-2-yl]-4-methyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide

InChI  InChI=1S/C23H41N5O5S/c1-13(2)12-14(17(29)26-16(19(31)24-8)22(3,4)5)25-18(30)15(34)10-11-28-20(32)23(6,7)27(9)21(28)33/h13-16,34H,10-12H2,1-9H3,(H,24,31)(H,25,30)(H,26,29)/t14-,15-,16+/m0/s1

InChI_Key GTXSRFUZSLTDFX-HRCADAONSA-N

SMILES  CC(C[C@@H](C(N[C@H](C(NC)=O)C(C)(C)C)=O)NC([C@H](CCN(C1=O)C(C(C)(N1C)C)=O)S)=O)C

External Codes


PubChem CID  9913881

DrugBank Accession Number  DB06573

NCI Thesaurus Code  C1875  

UNII  1B47R6ZX4K   GSRS

CAS  259188-38-0



Drug approval


Drug indication
    Investigated for use/treatment in lung cancer and prostate cancer.

    The drug is not approved.

ClinicalTrials.gov Identifier Title Condition or disease Phase Purpose
NCT00040755 Randomized Phase II Trial of BMS-275291 (NSC 713763, IND 62573) in Hormone Refractory Prostate Cancer Adenocarcinoma of the Prostate; Bone Metastases; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer; Stage IV Prostate Cancer Phase 2 Treatment
NCT00039104 A Phase II, Open-Label, Randomized Trial of Zoledronic Acid (Zometa™) and BMS-275291 (NSC#713763) in Patients With Hormone Refractory Prostate Cancer Adenocarcinoma of the Prostate; Recurrent Prostate Cancer; Stage IV Prostate Cancer Phase 2 Treatment
NCT00024024 A Phase I-II Trial Of BMS-275291 In Patients With HIV-Related Kaposi's Sarcoma Sarcoma Phase 1/2 Treatment
NCT00006229 A Phase II/III Double Blind Randomized Trial of BMS-275291 vs. Placebo in Patients Receiving Paclitaxel/Carboplatin Chemotherapy for the Treatment of Advanced or Metastatic Non-small Cell Lung Cancer Lung Cancer Phase 2/3 Treatment

    More clinical information is obtained from ClinicalTrials.gov.





DRACP is developed by Dr.Zheng's team.